Inhalable biohybrid microrobots: a non-invasive approach for lung treatment
Top Cited Papers
Open Access
- 14 January 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Abstract
Amidst the rising prevalence of respiratory diseases, the importance of effective lung treatment modalities is more critical than ever. However, current drug delivery systems face significant limitations that impede their efficacy and therapeutic outcome. Biohybrid microrobots have shown considerable promise for active in vivo drug delivery, especially for pulmonary applications via intratracheal routes. However, the invasive nature of intratracheal administration poses barriers to its clinical translation. Herein, we report on an efficient non-invasive inhalation-based method of delivering microrobots to the lungs. A nebulizer is employed to encapsulate picoeukaryote algae microrobots within small aerosol particles, enabling them to reach the lower respiratory tract. Post nebulization, the microrobots retain their motility (~55 μm s-1) to help achieve a homogeneous lung distribution and long-term retention exceeding five days in the lungs. Therapeutic efficacy is demonstrated in a mouse model of acute methicillin-resistant Staphylococcus aureus pneumonia using this pulmonary inhalation approach to deliver microrobots functionalized with platelet membrane-coated polymeric nanoparticles loaded with vancomycin. These promising findings underscore the benefits of inhalable biohybrid microrobots in a setting that does not require anesthesia, highlighting the substantial translational potential of this delivery system for routine clinical applications.Keywords
Funding Information
- United States Department of Defense | Defense Threat Reduction Agency (HDTRA1-24-1-0019, HDTRA1-21-1-0010)
This publication has 49 references indexed in Scilit:
- Microrobots for Minimally Invasive MedicineAnnual Review of Biomedical Engineering, 2010
- Green Evolution and Dynamic Adaptations Revealed by Genomes of the Marine Picoeukaryotes MicromonasScience, 2009
- Inhaled nanoparticles—A current reviewInternational Journal of Pharmaceutics, 2008
- Targeted delivery of magnetic aerosol droplets to the lungNature Nanotechnology, 2007
- Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001 05Journal of Antimicrobial Chemotherapy, 2007
- Inhaling medicines: delivering drugs to the body through the lungsNature Reviews Drug Discovery, 2007
- A Single Species, Micromonas pusilla (Prasinophyceae), Dominates the Eukaryotic Picoplankton in the Western English ChannelApplied and Environmental Microbiology, 2004
- Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophagesInternational Journal of Pharmaceutics, 2004
- Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.2003
- Intratracheal Instillation as an Exposure Technique for the Evaluation of Respiratory Tract Toxicity: Uses and LimitationsToxicological Sciences, 2000